SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (7562)12/20/2002 12:22:07 PM
From: Biomaven  Respond to of 52153
 
Harold,

Yes, indeed, DOVP still looks very cheap with an $85MM market cap, this royalty and a drug starting Phase III, particularly as it's also sitting on about $60m of cash and marketable securities. I bought some a month or so back at around $5.00 and added a little more yesterday.

They have a lawsuit about their bungled IPO, but I doubt the company will have to pay much, if anything.

Peter



To: Harold Engstrom who wrote (7562)12/20/2002 1:14:08 PM
From: Michael Young  Read Replies (1) | Respond to of 52153
 
I've been following DOVP closely since the summer. I believe they may have three drugs in Phase III next year, including indiplon. The other drugs appear to address decent size markets, but I'm not sure about the odds of success.

The stock would probably be trading over $10 but for the IPO fiasco.

MIKE


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News